pharma · Metastatic Colorectal Cancer · Duchenne Muscular Dystrophy · SMMT
Summit Therapeutics
Summit Therapeutics clinical programs — 23 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US
- Founded
- 2003
- Employees
- 367
- Programs
- 41
- Drugs
- 32
- Patents
- 20
Summit Therapeutics projects
23 ClinicalTrials.gov programs sponsored by Summit Therapeutics.
Summit Therapeutics has 23 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AK112
Summit Therapeutics
Metastatic Colorectal Cancer
1 trial -
Ezutromid
Summit Therapeutics
Duchenne Muscular Dystrophy
1 trial -
Hyperbaric Oxygen Therapy
Summit Therapeutics
TBI Traumatic Brain Injury
1 trial -
Ivonescimab
Summit Therapeutics
Cutaneous Squamous Cell Carcinoma
1 trial -
Ivonescimab
Summit Therapeutics
Endometrial Cancer
1 trial -
Ivonescimab
Summit Therapeutics
Glioblastoma
1 trial -
Ivonescimab
Summit Therapeutics
Ivonescimab
1 trial -
Ivonescimab
Summit Therapeutics
Leiomyosarcoma
1 trial -
Ivonescimab
Summit Therapeutics
Lung Cancer (NSCLC)
1 trial -
Ivonescimab
Summit Therapeutics
Advanced Head and Neck Squamous Cell Carcinoma
1 trial -
Ivonescimab
Summit Therapeutics
Biliary Tract Cancer
1 trial -
Ivonescimab
Summit Therapeutics
Salivary Gland Cancer
1 trial -
Ivonescimab
Summit Therapeutics
Stomach Cancer Stage IV
1 trial -
Ivonescimab
Summit Therapeutics
Thymus Carcinoma
1 trial -
Ivonescimab
Summit Therapeutics
TNBC
1 trial -
Ivonescimab
Summit Therapeutics
Metastatic Colorectal Cancer
2 trials -
Ivonescimab
Summit Therapeutics
Metastatic Esophageal Adenocarcinoma
1 trial -
Ivonescimab
Summit Therapeutics
Non-Small Cell Lung Cancer
3 trials -
Ivonescimab
Summit Therapeutics
Pleural Mesotheliomas
1 trial -
Ivonescimab 10 mg/kg
Summit Therapeutics
Extensive Stage Lung Small Cell Cancer
1 trial -
Nebivolol Ophthalmic Suspension 1 Percent
Summit Therapeutics
Open-Angle Glaucoma
1 trial -
Ridinilazole
Summit Therapeutics
Clostridium Difficile Infection
1 trial -
SMT19969
Summit Therapeutics
Clostridium Difficile Infection
1 trial
Frequently asked questions
How many clinical projects does Summit Therapeutics have?
23 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.